Drug firm Natco Pharma today reported an over five-fold jump in its consolidated net profit to Rs 195.08 crore for the third quarter ended December 31, 2016 mainly on account of Oseltamivir sales in the US.
The company had posted a net profit after non-controlling interests of Rs 36.93 crore for the corresponding period of the previous fiscal, Natco Pharma said in a filing to BSE.
Consolidated total income from operations also rose to Rs 679.01 crore for the quarter under consideration as against Rs 288.09 crore for the same period year ago.
"The revenue and profit growth for the company during the quarter was driven predominantly by the sales of Oseltamivir product in the USA market and includes profit sharing from our marketing partner," Natco Pharma said.
In another filing to the bourses, the company said its board has declared second interim dividend of Rs 6 on each equity share of Rs 2 each for the year 2016-17.
Shares of Natco Pharma today closed at Rs 778.70 per scrip on BSE, up 1.68 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
